In conjunction with other prognostic tools, SChLAP1 has been shown to improve upon established clinical algorithms for the risk stratification of PCa patients, specifically the CAPRA-S score (53, 54), i.e., one of the best clinic-pathological models to date. This evidence concerns the gene SCHLAP1 and posterior cortical atrophy.